cyrilzakka/clinical-trials huggingface dataset:
Testing Informed Decision Making in Lung Cancer Screening

Lung cancer screening rates are very low despite the fact that lung cancer screening could save many lives. People need to understand the risks and benefits to screening as well as their own beliefs about screening. This study builds an intervention in real world primary care that will help people make the right decision for them as well as help people to quit smoking. Interventions like this are needed to improve the screening rate and reduce death from lung cancer, which is the leading cancer killer.

Lung cancer screening rates in the United States are very low- just 3.3% in 2010 and 3.9% in 2015. There is a critical need to develop and implement effective strategies to engage high-risk patients in a coordinated program of lung cancer screening, which includes shared-decision making. The investigators proposed to modify and expand a shared decision- counseling intervention previously developed in one primary care practice. The investigators measured lung cancer screening in our intervention group compared to a propensity-matched usual care cohort. The investigators compared patients recruited to patients who are not in order to identify potential sources of disparity in future work and the investigators developed a more intense smoking cessation component. Model interventions for shared-decision making in clinical practice are needed across a wide range of diseases and decisions.

Eligibility Criteria:
Inclusion Criteria:

* Current or former smoker
* Greater than or equal to 30 pack years smoking

Exclusion Criteria:

* Prior CT in last year
* Quit smoking greater than 15 years ago
* Current diagnosis of lung cancer
Electronic Reporting of Symptoms After Surgery

The purpose of this pilot study is to find out if patients are willing to self-report symptoms in the first 5 days following discharge, or when they leave the hospital after "ambulatory surgery" ("ambulatory surgery" is when the patient has surgery and then goes home within 24 hours).


Eligibility Criteria:
Inclusion Criteria:

* The patients must be undergoing surgery for an indication tracked within the Gynecologic AXR program or have an expected postoperative discharge within 24 hours of surgery. These surgical procedures typically include: minimally invasive hysterectomy or radical hysterectomy, salpingo-oophorectomies \[mentioned above\], and minimally invasive staging procedures.
* The patient must have a phone number or an email address.
* The patient must be willing to self-report postoperative symptoms over an automated phone system or via an online platform.
* The patient must speak and read fluent English.

Exclusion Criteria:

* Non-English speaking patients
* Patients unwilling to provide contact information (email or phone number)
Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC

The study will recruit 150 patients with HCV related HCC ,after HCC treatment the patients will undergo treatment with different regimens of DAAs.

The study will recruit 150 patients with HCV related HCC All the studied patients underwent or will undergo one of the curative interventions for HCC either hepatic resection or thermal ablation .

after 1 month of achievement of laboratory and radiological response to HCC intervention the patient will be treated with one of the interferon free regimens :

1. Sofosbuvir+Ribavirin
2. Sofosbuvir+Simeprevir± Ribavirin
3. Sofosbuvir+ Daclatasvir ± Ribavirin
4. Sofosbuvir+ Ledipasvir ± Ribavirin

the treatment duration will be justified either 12 or 24 weeks after treatment the patient will continue on regular follow up to detect HCV cure or recurrence , HCC cure or recurrence and long term follow up of natural history

Eligibility Criteria:
Inclusion Criteria:

* Age 18-70 years old
* Confirmed HCV viremia by PCR
* CHILD Pugh "A" or "B7,B8"
* Confirmed HCC either by laboratory ,imaging or histopathological criteria
* Underwent or candidate for curative intervention for HCC (BCLC stage 0 ,A)
* Willing to be treated for HCV and signing informed consent

Exclusion Criteria:

* Patients below 18 or above 70 years old
* patients with advanced liver condition "CHILD score ≥ B9"
* Patients with advanced HCC status (BCLC≥ B)
* Patients with combined HBV ,HIV infection
Response to Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced Oral Cancer

The goal of this observational study is to investigate the effectiveness of neoadjuvant chemoimmunotherapy (NACI) regimens in treating advanced oral squamous cell carcinoma (OSCC) patients. We analyzed clinicopathologic features of advanced OSCC patients who received PD-1 inhibitors in combination with carboplatin and paclitaxel before surgical tumor resection between 2020 and 2022. The Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) and pathologic response were used to evaluate the efficacy of the NACI treatment. Adverse events apparently related to NACI treatment were graded according to the Common Terminology Criteria for Adverse Events, version 4.0. Disease-free survival (DFS) and overall survival (OS) were calculated using the Kaplan-Meier survival curves and compared using the log rank test. Additionally, we calculated the area under curve (AUC) to compare the predictive value of PD-L1 expression with baseline serum lipid biomarkers for patient response.


Eligibility Criteria:
Inclusion Criteria:

Patients with advanced OSCC who received NACI before surgery

* Confirmation of primary OSCC by two experienced pathologists;
* Clinical stage III/ IVA (cT1-2/cN1-2/M0 or cT3-4a/cN0-2/M0) according to the 8th Edition of American Joint Committee on Cancer (AJCC) guideline;
* An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1;
* No prior anti-cancer therapy;
* Locally resectable advanced tumor evaluated by a head and neck surgeon.

Advanced OSCC patients who only received surgery

* A histopathologic diagnosis of primary OSCC;
* A clinical stage of III/IVA (AJCC, 8th edition);
* An ECOG performance status of 0 to 1.

Exclusion Criteria:

Patients with advanced OSCC who received NACI before surgery

* Patients with other pathological types, without NACI or Surgery;
* Incomplete pre-treatment data;
* Lost to follow up were excluded from the study.

Advanced OSCC patients who only received surgery

* Patients who had received other therapies targeting the head and neck region before the surgery or those with evidence of recurrence or metastasis, as assessed by physical examination reports or imaging studies before surgery
* Lost to follow up.
Impact of Strained Interpersonal Relationship (IPR) With Parents on Juvenile Delinquency Among Children

"Assess the impact of Strained Interpersonal Relationship (IPR) with parents on Juvenile Delinquency among Children residing in Selected Delinquent Home Ambala, Haryana"

The objectives of this study are:- To assess and compare IPR score with parents among case (delinquent children) and control (non delinquent children) group.

To determine the association of IPR score with selected variables among case (delinquent children) and control (non delinquent children) group.

Eligibility Criteria:
Inclusion Criteria:

children who were aged 13-18 years and residing in selected delinquent home, ambala (for case).

aged 13- 18 years, fulfils matching (age) and homogenity(gender) with case and studing in selected school, Barara (for control).

alert, oriented and able to read, comprehend and speak English/ hindi.

Exclusion Criteria:

children who were non-literate (for case) not willing to participate in study. not having both biological parents.
Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months

Multi-center, observational, active safety surveillance study in participants aged 6 to 35 months in Korea under routine clinical practices.

The planned duration of each participant's participation in the study will be 21 to 28 days.

Eligibility Criteria:
Inclusion Criteria:

* Aged 6 to 35 months on the day of enrolment
* Informed consent form has been signed and dated by the parent or other legally acceptable representative
* Receipt of one dose of VaxigripTetra® on the day of inclusion in routine practice according to the approved local product insert

Exclusion Criteria:

- Participation at the time of study enrolment (or in the 4 weeks preceding the enrolment) or planned participation during the present study period in a clinical study investigating a vaccine, drug, medical device, or medical procedure
Pregabalin add-on for Neuropathic Pain in Cervical Myelopathy

There is no information on the effect of pregabalin in patients with neuropathic pain in cervical myelopathy under routine clinical practice.

The investigators will conduct this prospective, randomized trial to determine the efficacy of pregabalin for neuropathic pain in cervical myelopathic patients in order to validate or refute this popular practice. The primary aim of this study was to compare Leeds assessment of neuropathic symptoms and signs scale (LANSS) scores of neuropathic pain in cervical myelopathy patients.

Neuropathic pain is a well-recognized clinical entity. It is defined as pain caused by the lesion or dysfunction of the peripheral or central nervous system, and it can be diagnosed by well-established clinical criteria. Neuropathic pain is caused by lesions or dysfunction of the nervous system and is initiated by several cellular and molecular mechanisms. Compression of neural and neurovascular structures may result in neuropathic pain. Although a number of therapies are available for neuropathic pain, including antidepressants, tramadol, opioids, and different antiepileptic drugs, the results of a recent systematic review suggest that, in view of their balance between efficacy and tolerability, pregabalin can be regarded as first line treatments for peripheral pain with a neuropathic component.

Pregabalin is one of antiepileptic drugs (AEDs) that have been studied in the treatment of a wide variety of disorders, such as neuropathic pain, epilepsy, spasticity, and anxiety. The use of AEDs in the treatment of neuropathic pain is based on a number of similarities in the pathophysiologic and biochemical mechanisms underlying neuropathic pain and epilepsy. Its use for the treatment of several neuropathic pain syndromes is common, and it is approved by the Food and Drug Administration (FDA) for the treatment of diabetic neuropathy, post-herpetic neuralgia, fibromyalgia and spinal cord injury, a model of central neuropathic pain. The off-label use of pregabalin for the various pain syndromes in general, and for neuropathic pain in particular, is ubiquitous. However, minimal support for this practice exists in the literature and its cost is perhaps exorbitant. There is no information on the effect of pregabalin in patients with neuropathic pain in cervical myelopathy under routine clinical practice.

Eligibility Criteria:
Inclusion Criteria:

1. between the ages of 18 to 80 years
2. Among patients with cervical myelopathy, patients with neuropathic pain (LANSS pain scale ≥ 12)
3. Completing 8-week drug trial

Exclusion Criteria:

1. Current or prior gabapentin or pregabalin use
2. Chronic use of narcotic pain medications
3. Chronic depression or the use of anti-depressants
4. History of addiction and/or substance abuse
5. Presence of significant motor deficits, and /or bowel and/or bladder dysfunction
6. Known renal insufciency, diabetes, congestive heart failure, cardiac conduction abnormalities, and thrombocytopenia
Lifestyle Related Disease Management With Wearable Device and Mobile Application

In order to study the effectiveness of personalized healthcare intervention for lifestyle-related diseases, investigators designed this study using mobile application and clinical feedback coaching.


Eligibility Criteria:
Inclusion Criteria:

* Study participants must agree to support by him/herself at enroll time
* Patient without severe cardiopulmonary disease, cancer, or other acute diseases
* Patient must be over BMI \> 23 kg/m2

Exclusion Criteria:

* Patient who did not agree with this study
* Patient with severe cardiopulmonary disease, cancer, or other acute diseases
* Patient who are pregnant
Can Primary Care Change Elderly Physical Activity and Salt Intake? An Australian Pilot Trial

A randomised controlled trial to test if offering three visits to a dietician + two visits to a physiotherapist over six months + a home sphygmomanometer, will result in a reduction in sodium intake and an increase in fitness in people over 75yrs. Volunteers were enrolled from Oct 2008 to July 2009.

There is evidence that both sedentary lifestyle and high sodium diets contribute to cardiovascular disease and possibly dementia among the elderly. There is a need to show that minimal intervention can reduce sodium intake and increase fitness in the elderly. Finland has shown that five dietician visits/year could change diet in respect to fat and fibre. In Australia the National Health Insurer (Medicare) funds five allied health visits/year for those with chronic disease, hence our use of this model. This is consistent with WHO guidelines for a national approach using existing health infrastructure. The elderly (75-95yrs) were chosen as this group is thought most difficult to change behaviour and has a higher incidence of dementia.

Eligibility Criteria:
Inclusion Criteria:

* Living independently
* Must be able to walk for six minutes

Exclusion Criteria:

* Dementia as defined by Standardised Mini-Mental State Examination score \<25/30
* All patients of HealthHQ-Southport General Practice
A Clinical Study for the Effect of 4th Generation Poly AmidoAmine Dendrimer on Post-Bleaching Hypersensitivity and Shade Stability

This study assessed the impact of four desensitizing agents on both color stability and dental sensitivity following a bleaching procedure, spanning from the 24-hour to the 1-year follow-up assessment periods.

Dental bleaching is a temporary treatment with potential adverse effects on dental sensitivity post-procedure. Therefore, the study aimed to evaluate dental color stability and sensitivity over a one-year period following bleaching, utilizing one of four desensitizing agents: PAMAM, MI Paste Plus, Hydroxyapatite and F (ReminPro), and Ultra EZ. The selection of the desensitizing agent was based on a predetermined randomization sequence generated in Microsoft Excel. Color stability was objectively assessed through spectrophotometric analysis, while subjective evaluation was conducted using the Vita Classic shade guide by two external observers not involved in the procedure. Dental sensitivity levels were tracked at various intervals using a visual analogue scale. Baseline measurements for both sensitivity and color stability were taken before the bleaching procedure, with subsequent evaluations at 24 hours, 3 days, 1 week, 1 month, 3 months, 6 months, 9 months, and 1 year post-bleaching. The study involved 60 patients from Ain Shams University seeking dental whitening treatment, divided into four groups based on the randomization sequence.

Eligibility Criteria:
Inclusion Criteria:

Male and female patients will be selected according to the following inclusion criteria:

* Participants should have their entire upper and lower teeth, from right first premolar to left first premolar, present and sound, without restorations or periodontal disease.
* Teeth have never been bleached before.
* The participants are required to have low-caries index.
* Teeth should have a Vita-color shade of A2 or darker.
* Cooperative behavior patient and medically free.
* Patient ages between 18 to 40 years old.

Exclusion Criteria:

* Serious medically compromised patients.
* Smoking, alcoholism.
* Hypersensitivity to the agents used in the study.
* Lactated, pregnant patients.
* Patients have serious oral diseases, as acute necrotizing gingivitis, acute gingiva stomatitis, or undergoing orthodontic treatment.
* Patients with dental enamel cracks.
* Patients who had previous bleaching treatments
Vanderbilt ICU Recovery Program Pilot Trial

Every year, millions of Americans are admitted to the intensive care unit. Due to advances in critical care, mortality rates are decreasing, increasing the number of ICU survivors. Survivors of critical illness, however, often face physical, functional, and cognitive deficits that place them at risk for a cycle of re-hospitalization that frequently culminates in premature death. Moreover, post-ICU interventions may be resource-intensive and may be most cost-effective only in a subgroup of patients at highest risk. Whether a multi-disciplinary program to facilitate recovery from critical illness can prevent hospital readmission and improve quality of life among high-risk ICU survivors remains unknown. The primary aim of this pilot is to examine the feasibility of implementing a multidisciplinary ICU Recovery Program and the influence of such a program on process measures including contact with the ICU recovery team and attendance of ICU recovery clinic. The secondary aims are to compare the effect of an ICU Recovery Program on 30-day same-hospital readmission and other clinical outcomes.


Eligibility Criteria:
Inclusion Criteria:

1. Age ≥ 18 years
2. Admitted to the Medical Intensive Care Unit (MICU) at Vanderbilt University Medical Center for at least 48 hours
3. Estimated risk of 30-day same-hospital readmission greater than 15%
4. Not previously enrolled in the study.

Exclusion Criteria:

1. Long-term residence at a skilled nursing facility
2. Long-term mechanical ventilation prior to admission
3. Solid organ or stem cell transplantation
4. Recorded primary residency \> 200 miles from Vanderbilt
5. Comfort care only
Comparison of the Efficacy of Boric Acid Mouthwashes in Different Concentrations

Surgical removal of impacted third molars is one of the most frequent procedures carried out in the oral and maxillofacial surgery clinics. There are a varying range of postoperative complications including pain, edema and swelling. Antibiotics, analgesics and mouthwashes are usually prescribed for the treatment of these complications. Patients undergoing impacted third molar surgery are frequently prescribed chlorhexidine mouthwashes with/without benzydamine hydrochloride. However, there has been a search for alternatives with anti-inflammatory, antibacterial and analgesic properties as part of the oral care routine following surgical removal of impacted third molars. Thus, this multicenter study was aimed to evaluate the effects of chlorhexidine mouthwashes with different boric acid concentrations (%0.1, %0.5, %1, %1.5, %2 and %2.5), and boric acid mouthwash on the postoperative complications and compared with chlorhexidine mouthwash after the removal of impacted wisdom teeth.


Eligibility Criteria:
Inclusion Criteria:

* absence of any systemic disease
* having impacted mandibular third molar teeth in a similar position
* absence of allergy to any of the drugs used in the study,
* absence of pregnancy/lactating state,
* no history of any medication use during at least 2 week before the operation.

Exclusion Criteria:

* not regularly coming to the controls,
* not using their medicines regularly
* using any additional medication that may affect the outcome of the study
Post Marketing Surveillance Study for ADYNOVATE in South Korea

The main aim of this study is to check for side effects and medical problems in participants with hemophilia A who are receiving ADYNOVATE in routine clinical practice. Also, it will be checked how effective ADYNOVATE is at stopping a bleed, at preventing bleeding episodes when used routinely for prevention and at controlling hemophilia-related bleeding during surgeries.

Participants with hemophilia A who will be newly prescribed with ADYNOVATE treatment or have already been taking ADYNOVATE treatment according to the physician's decision will be included in this study.

Participants will visit the study clinic as a part of their routine clinical practice and will be contacted by phone calls/home visits by home care workers for collection of treatment related data during the 6-month observation period.


Eligibility Criteria:
Inclusion Criteria

Participants with a diagnosis of hemophilia A who will be newly prescribed with ADYNOVATE or already have been prescribed ADYNOVATE according to the study physician's judgment shall be included in this study if:

* The participant or legally authorized representative has given written informed consent to participate in the study.
* The participant is indicated for treatment according to the ADYNOVATE South Korea prescribing information (PI).

Exclusion Criteria

Participants should be excluded from this study if:

* The participant or legally authorized representative does not wish to participate in the study.
* Any of the contraindications included in the PI for ADYNOVATE apply.
* Participant is enrolled in an interventional trial using an investigational product other than ADYNOVATE.
Innovative Multigenerational Household Intervention to Reduce Stroke and CVD

American Indians (AI's) are experiencing an epidemic of stroke morbidity and mortality, with higher prevalence and incidence, younger age at onset, and poorer survival than other racial and ethnic groups. With a stroke incidence more than twice that of the general U.S. population, stroke in AI's is a public health problem of staggering scope. AI's also have disproportionate burdens of many risk factors for stroke, including hypertension, smoking, obesity, and diabetes. However, no rigorous, population-based studies of stroke prevention have included AI's. The investigators at WSU, and community partners, have designed the "Family Intervention in the Spirit of Motivational Interviewing" (FITSMI), a program delivered at the household level to encourage lifestyle changes that transform the home environment and reduce stroke risk for all residents. FITSMI uses a "talking circle" format in which facilitators guide participants to identify goals for change and create a tailored plan for sustainable implementation that may target smoking, exercise, diet, or medication adherence. FITSMI requires just 2 sessions (baseline and 1 month post-baseline), with text messaging used to boost long-term adherence. In a group-randomized trial design, the investigators will recruit 360 households where Strong Heart Family Study members aged 45 and older reside. The investigators will assign half to FITSMI and half to a control condition that receives educational brochures.


Eligibility Criteria:
Inclusion Criteria:

* Household must include one member over the age of 45 (index participant)

Exclusion Criteria:

* Under the age of 11